Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: Right growth prescription` - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 24, 2003

    Ranbaxy: Right growth prescription`

    Ranbaxy has recorded an 11% increase in revenues and a strong 42% increase in bottomline. Exports constituted 64% of the total revenues. For 1HFY04, Ranbaxy has reported a 51% increase in topline and 59% increase in bottomline.

    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Net Sales 7,448 8,277 11.1% 13,158 19,174 45.7%
    Other Income 25 931 3624.0% 55 987 1694.5%
    Operating expenses 5,827 6,642 14.0% 10,584 14,112 33.3%
    Operating Profit (EBDIT) 1,621 1,635 0.9% 2,574 5,062 96.7%
    Operating Profit Margin (%) 21.8% 19.8%   19.6% 26.4%  
    Interest (net) 53 17 -67.9% 181 23 -87.3%
    Depreciation 203 188 -7.4% 401 367 -8.5%
    Profit before tax and extraordinary items 1,390 2,361 69.9% 2,047 5,659 176.5%
    Extra-ordinary Items 356 48 -86.5% 920 97 -89.5%
    Tax 362 441 21.8% 634 990 56.2%
    Profit after Tax 1,384 1,968 42.2% 2,333 4,766 104.3%
    Net profit margin (%) 18.6% 23.8%   17.7% 24.9%  
    No. of Shares (eoy) (m) 116.0 185.0   116.0 185.0  
    Diluted earnings per share* 29.9 42.6   25.2 51.5  
    P/E ratio   19.1     15.8  
    (* annualised)            

    Other income has seen a sharp rise on account of the the company receiving its share of revenues from Bayer for the sale of Ciprofloxacin OD. An increase in the R&D expenditure from Rs 365 m to Rs 486 m has resulted in a marginal drop in the operating margins.

    Consolidated results snapshot
    Rs m 2QFY03 2QFY04 Change
    Sales 9,585 11,349 18.4%
    Operating Profit 2,061 3,130 51.9%
    Operating Margins (%) 21.5% 27.6%  
    Net Profit 1,709 2,062 20.7%
    Net Margins (%) 17.8% 18.2%  

    Ranbaxy had restructured its debt portfolio by borrowing US$ 10 m through the ECB route and repaying its high cost debt. The company has thus been able to bring down its interest cost by 38%. This coupled with a drop in the depreciation expenses has helped Ranbaxy record a sharp improvement in its net margin. On a consolidated basis, Ranbaxy has registered an 18% growth in the topline and a 21% increase in the bottomline during the quarter.

    The stock is currently trading at Rs 812 implying a P/E of 16x its annualised 1HFY04 earnings. Considering Ranbaxy’s strong growth potential in the generics segment, which has been given a boost with the US government reducing the time period for drug approval and the inclusion of generics in the US government sponsored 'Medicare' policy, combined with its focus on developing a strong NCE and ANDA pipeline, the company has good long-term prospects. However, the risk profile of the stock is also on the higher end given the inherent risks involved in NCE research and complex regulatory procedures on the ANDA front.



    Equitymaster requests your view! Post a comment on "Ranbaxy: Right growth prescription`". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Apr 1, 2015 (Close)


    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks